10-13-2015, 11:13 PM
Sunil,
Your assumption is right that the goal is to remove HCP from a therapeutic product. This is a generic assay used for many different products. The pAbs are derived from goats immunized with null cell lines. My concern is that when running the pAbs over a column to reduce background is if I see a reduction in high end binding. This would make me think I am losing a portion of the specific antibodies as well. For this reason I would be compelled to ensure that my coverage has remained the same (compare coverage pre-adsorbtion and post-adsorption).
Thank you for your input.
Your assumption is right that the goal is to remove HCP from a therapeutic product. This is a generic assay used for many different products. The pAbs are derived from goats immunized with null cell lines. My concern is that when running the pAbs over a column to reduce background is if I see a reduction in high end binding. This would make me think I am losing a portion of the specific antibodies as well. For this reason I would be compelled to ensure that my coverage has remained the same (compare coverage pre-adsorbtion and post-adsorption).
Thank you for your input.
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)